IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance

Joanna Selfe1*, Neil C Goddard1, Alan McIntyre1, Kathryn R Taylor2, Jane Renshaw1, Sergey D Popov2, Khin Thway3, Brenda Summersgill1, Robert A Huddart4, Duncan C Gilbert1,3 and Janet M Shipley1*

1 Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, Institute of Cancer Research, London, UK
2 Glioma Team, Divisions of Molecular Pathology and Cancer Therapeutics, Institute of Cancer Research, London, UK
3 Sarcoma Unit, Department of Histopathology, The Royal Marsden NHS Foundation Trust, London, UK
4 Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, Sutton, UK
5 Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK

*Correspondence to: Janet Shipley, Sarcoma Molecular Pathology Team, MUCRC, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. E-mail: janet.shipley@icr.ac.uk
†These authors contributed equally to this work.

Abstract

Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy, this is associated with long-term toxicities and chemo-resistance. Roles for receptor tyrosine kinases other than KIT are largely unknown in TGCT. We therefore conducted a phosphoproteomic screen and identified the insulin growth factor receptor-1 (IGF1R) as both highly expressed and activated in TGCT cell lines representing the nonseminomatous subtype. IGF1R was also frequently expressed in tumour samples from patients with nonseminomas. Functional analysis of cell line models showed that long-term shRNA-mediated IGF1R silencing leads to apoptosis and complete ablation of nonseminoma cells with active IGF1R signalling. Cell lines with high levels of IGF1R activity also showed reduced AKT signalling in response to decreased IGF1R expression as well as sensitivity to the small-molecule IGF1R inhibitor NVP-AEW541. These results were in contrast to those in the seminoma cell line TCAM2 that lacked IGF1R signalling via AKT and was one of the two cell lines least sensitive to the IGF1R inhibitor. The dependence on IGF1R activity in the majority of nonseminomas parallels the known role of IGF signalling in the proliferation, migration, and survival of primordial germ cells, the putative cell of origin for TGCT. Uptregulation of IGF1R expression and signalling was also found to contribute to acquired cisplatin resistance in an in vitro nonseminoma model, providing a rationale for targeting IGF1R in cisplatin-resistant disease.

Keywords: testicular germ cell tumours; nonseminomas; IGF1R; receptor tyrosine kinase

Received 9 June 2017; Revised 7 November 2017; Accepted 14 November 2017

No conflicts of interest were declared.

Introduction

Testicular germ cell tumours (TGCTs) are the most common solid malignancy in young adults and adolescents. They comprise two major histological subtypes: seminomas, which resemble primordial germ cells (PGCs), the likely precursors of TGCT; and nonseminomas, which display features of embryonic, extra-embryonic, and somatic tissue. TGCTs are thought to originate through improper development of PGCs and/or gonocytes (reviewed in ref 1). Signalling through the KIT receptor tyrosine kinases (RTKs) is important in this process, as this, and more recently IGF1R, has been shown to promote the motility and survival of PGCs [2–4].

Over 95% of patients presenting with TGCT are cured, either through orchidectomy at an early stage or by the effective use of combination cisplatin-based chemotherapy [5]. Patients who present with poor risk features (extremely high tumour markers, non-pulmonary visceral metastases or mediastinal primary tumour) have survival rates below 70% and despite initial favourable responses, cisplatin resistance can develop [6]. The typically young age at diagnosis means that, on average, approximately 36 years of life are lost per man dying of TGCT from an average 81.5 years’ life expectancy in the UK [6]. Overcoming chemo-resistance is key to improving survival in poor prognosis patients.

Inhibition of RTKs has realized their therapeutic potential in a range of cancers over the past decade. Humanized monoclonal antibodies such as trastuzumab (ERBB2 inhibitor) and bevacizumab (VEGF inhibitor) successfully target either the RTK or its ligand to block downstream signalling. Small-molecule inhibitors of
IGF1R signalling in TGCT

Intracellular RTK signalling also have proven activity in many tumour types [e.g. imatinib and gastrointestinal stromal tumour (GIST), sunitinib and renal cell carcinoma, and erlotinib in non-small cell lung cancer [7–9]]. Previous work by us and others has shown the involvement of RTK signalling in seminomas (SEs) by showing that the gene encoding KIT is amplified (21% of SEs) [10,11], expressed (78–100% of SEs) [12–15], and mutated (10–25% of SEs), together suggesting a strong selection pressure for KIT signalling in SE [16–18]. A reduction in viability in response to siRNA-mediated silencing of KIT in SE cells suggests dependency in this cell type [19].

There is growing evidence that indicates a role for activation of the RAS, MAP kinase, and PI3-kinase pathways in both the seminoma and the nonseminomatous subtypes of TGCT [20–22]. Downstream elements of RTK signalling activated in TGCT include genomic gain of RAS in 10% and loss of inhibitory factors such as PTEN [20] and PIK3IP1 [22]. Gain of 12p is a hallmark of TGCT and the minimum region of amplification almost invariably includes the KRAS gene [10,23]. Upregulation of RAS signalling occurs through activating mutations of RAS genes (KRAS, NRAS, and HRAS) with a combined frequency of 8% [24,25]. Activating BRAF mutations are reported in 9% of seminomas and have been linked with a poorer prognosis [25,26]. However, ERK is constitutively active in TGCT, irrespective of the mutation status of upstream signalling components KIT, RAS or BRAF [16,25]. The PI3-kinase pathway is activated via loss of heterozygosity (36%), inactivating mutations (9%), and decreased expression of the PI3-kinase inhibitor PTEN (72%) in TGCT [20]. Additionally, genome-wide association studies have implicated polymorphisms in downstream effectors of RTKs in predisposition to TGCT [1,27]. Together, there is strong evidence for upregulation of pathways known to signal downstream of RTKs in both the seminoma and the nonseminoma subtypes of TGCT. However, evidence for which RTKs contribute to TGCT behaviour, beyond KIT in seminomas, is limited.

The aim of this study was to identify a role for specific RTK activity in TGCT. We first screened TGCT cell lines for RTK phosphorylation and identified IGF1R as phosphorylated in TGCT. High IGF1R activity was confirmed in TGCT samples and the dependence on IGF1R activity was demonstrated in nonseminoma cell line models, including a model of cisplatin resistance.

Materials and methods

Cell lines and tissue samples

The human cell lines GCT27, 577MF, TERA1, NTERA2, 2102 (2102EP), and GCT44 all represent nonseminomas (TCAM2 resembles seminomas) and were cultured as described previously [28–33]. SuSa (cisS), a human teratoma-derived cell line, and its cisplatin-resistant subline SuSa cisR have been described previously [34,35]. Samples were collected from TGCT patients (summarized in the supplementary material, Table S1) at the Royal Marsden Hospital NHS Foundation Trust. Informed consent was obtained from all patients; the study was approved by the Institute of Cancer Research/Royal Marsden Hospital Committee for Clinical Research (study number CCR2014) and procedures were in accordance with the Helsinki Declaration. Total RNA was extracted from frozen TGCT samples as described previously [24]. Normal tissue RNAs (smooth muscle, lung, uterus, skin, ovary, adipose, brain, stomach, bladder, thymus, placenta, thyroid, small intestine, spleen, pancreas, colon, bone marrow) were obtained from BD Biosciences (Palo Alto, CA, USA). TGCT formalin-fixed, paraffin-embedded tissues [see below for immunohistochemistry (IHC) and associated tissue microarrays (TMAs)] have been described previously [36].

Phospho RTK screen

The Human Phospho-RTK Array Kit (ARY001) (R&D Systems, Abingdon, UK) was used according to the manufacturer’s recommendations. This antibody-based technique simultaneously determines the levels of phosphorysine in 42 RTKs per sample. 5 × 10⁶ cells grown in normal serum were harvested and pelleted, and then resuspended in 500 μl of NP-40 lysis buffer and pre-cleared. Lysates were quantified using the Bio-Rad DC Protein Assay (Bio-Rad, Hemel Hempstead, UK).

Five hundred micrograms of cell line protein was added to each array and incubated for 16h at 2–8 °C before washing according to the manufacturer’s instructions. 1.5 ml of freshly diluted (1:2000) Anti-Phospho-Tyrosine-HRP Detection Antibody was added to each well and incubated for 2 h at room temperature. Arrays were developed using ECL Plus (GE Healthcare, Amersham, UK) according to the manufacturer’s instructions and activity was detected using the Molecular Imager ChemiDoc XRS System (Bio-Rad). The signal intensity was independently assessed on a grading system of 0–5 by three individuals and the consensus score was used (as described previously [37]). Each blot was also analysed by densitometry and each RTK intensity was expressed as a fraction of the total signal on the membrane. The ranking of RTK signal intensity by each method was highly similar.

Phospho-IGF1R ELISA

Cells were either unstimulated or stimulated with IGF-1 (Peprotech EC Ltd, London, UK) or IGF-2 (Peprotech EC Ltd) at 50 ng/ml in normal serum for 5 min prior to lysis. Cell lysates were quantified using the BCA Protein assay (Thermo Fisher Scientific, Waltham, MA, USA). The phospho-IGF1R ELISA assay (R&D Systems) was used according to the manufacturer’s instructions using 100 μg of protein per well. Absorbance at 450 nm was measured on an ELx800 Absorbance Microplate Reader (BioTek, Swindon, UK).
Immunoblotting

Protein was extracted from cell lines using lysis buffer [Cell Signaling Technology (CST), Leiden, The Netherlands]. Lysates were transferred onto polyvinylidene difluoride membrane using the iBlot system (Thermo Fisher Scientific) according to the manufacturer’s instructions. Antibodies (IGF1R (3027; CST), phospho-AKT (9271, Ser473; CST), AKT (9272; CST), phospho-IGF1R (Tyr1316) (6113; CST), phospho-STAT3 (Tyr705) (9145; CST), STAT3 (9139; CST), TUBA1A (α-tubulin) [sc-8035; Santa Cruz Biotechnology (SCBT), Dallas, TX, USA], ACTB (sc-47778; SCBT) and GAPDH (MAB374; 1:10 000; Merck Millipore, Watford, UK) were then removed and the beads washed according to the manufacturer’s instructions. Band intensities were digitally measured using ImageJ software [38,39].

Immunoprecipitation

Five hundred micrograms of whole cell lysate was adjusted to 1 μg/μl in cell lysis buffer and supplemented with activated sodium vanadate (final concentration 40 mM). IGF1R antibody (1:50 dilution; CST) or normal rabbit IgG (1 μg; SCBT) was added to diluted lysates and rotated overnight at 4 °C. Dynabeads Protein A (50 μl; Thermo Fisher Scientific) were added to lysates and rotated at 4 °C for 3 h. The supernatants were then removed and the beads washed according to the manufacturer’s instructions. Immunoprecipitated proteins were eluted by placing beads at 70 °C in 20 μl of 1x LDS Sample Buffer, 50 μM dithiothreitol (DTT; Thermo Fisher Scientific). The eluates were then subjected to immunoblotting.

Immunohistochemistry

Previously described TMAs [36] were deparaffinized and immunostained with a primary antibody for IGF1R (#3027; CST). Staining was performed on the Leica Bond III platform using Bond Polymer Refine DAB detection (Leica Biosystems, Newcastle-upon-Tyne, UK). Antibody was applied at a dilution of 1/200 for 15 min at room temperature, following on-board heat-mediated epitope retrieval using Leica Epitope Retrieval 2 solution (pH9) for 30 min at 99 °C (performed by University College London Advanced Diagnostics). Colon tissue sections were used as controls where discrete specific membranous staining of glandular cells was observed as expected. Slides were analysed by pathologists (SP and KT) and samples with at least two scorable cores were scored positive if more than 10% of cells showed membranous staining.

RT-qPCR

cDNA was produced from RNA using Superscript II reverse transcriptase (Thermo Fisher Scientific) according to the manufacturer’s instructions. Real-time RT-PCR was performed using the ABI PRISM 7900 Sequence Detection System according to the manufacturer’s instructions (Thermo Fisher Scientific). Pre-designed primer and probe sets for test (IGF1R Hs99999020_m1) and control (B-Actin 4310881E-0803023) genes were used (Thermo Fisher Scientific). Expression was averaged across triplicate repeats, quantified against a standard curve.

Copy number analysis

Copy number analysis was carried out using normal male genomic DNA as a calibrator (Promega, Southampton, UK) by real-time PCR on the Viia7 instrument (Thermo Fisher Scientific) according to the manufacturer’s instructions, using IGF1R copy number assay (Hs05381099_cn) and internal reference control gene (RPPH1) assay (Thermo Fisher Scientific). All reactions were performed in triplicate.

siRNA knockdown of target genes

Transfections were carried out according to the manufacturer’s instructions, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). siRNA duplexes that targeted IGF1R (Hs_IGF1R_1 HP,Hs_IGF1R_7 HP)(Qiagen, Hilden, Germany), and a non-targeting control siRNA (Dharmacon, Lafayette, CO, USA) at 33nM. Each transfection included six replicates.

Lentiviral transfection

shRNA sequences targeting IGF1R (MISSION® TRC shRNA TRCN0000000424; Sigma-Aldrich, Poole, UK) and a non-targeting control (SHC002; Sigma-Aldrich) were used in lentiviral shRNA knockdown. Lentivirus production and transduction were as previously described [40]. Two days post-transduction, cells were selected in either 2 μg/ml (NTERA2, GCT44, SuSa) or 5 μg/ml (TCAM2) puromycin.

Proliferation

Cellular proliferation was assessed using a CyQUANT NF Cell Proliferation Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Fluorescence intensity was measured (excitation at 485 nm, emission at 535 nm) using a VICTOR2 D fluorometer (PerkinElmer, Beaconsfield, UK). Cells were counted directly using a haemocytometer following lentiviral experiments.

GI50 assays

Cells were plated at 4000 cells per well in a 96-well plate. The following day, media were replaced with media containing NVP-AEW541 (Selleck Chemicals;
Table 1. RTK phosphorylation in TGCT cell lines using phospho arrays

| Antibody | GCT27 | GCT44 | 2102 | 577MF | TERA1 | TCAM2 | NTERA2 |
|----------|-------|-------|------|-------|-------|-------|--------|
| IGF1R    | 2     | 3     | 2    | 5     | 3     | 4     | 4      |
| INSR     | 2     | 3     | 2    | 4     | 3     | 3     | 3      |
| TYR03    | 3     | 2     | 3    | 3     | 3     | 3     | 3      |
| EPHB2    | 2     | 2     | 2    | 2     | 2     | 2     | 2      |
| EGFR     | 2     | 1     | 1    | 2     | N     | 2     | 3      |
| PDGFRB   | 0     | 2     | 2    | 1     | 3     | 1     | 1      |
| ROR1     | 2     | 1     | 2    | 1     | 2     | 2     | 2      |
| MSKR     | 1     | 1     | 2    | 2     | 1     | 2     | 2      |
| ROR2     | 1     | 1     | 2    | 3     | 1     | 1     | 1      |
| MERTK    | 1     | 1     | 1    | 2     | N     | 1     | 2      |
| TEK      | 1     | 1     | 1    | 2     | N     | 1     | 2      |
| FGFR2    | 0     | 1     | 1    | 2     | 3     | 0     | 1      |
| VEGFR2   | 0     | 1     | 1    | 2     | 3     | 0     | 1      |
| ERBB4    | 1     | 1     | 1    | 1     | 2     | 0     | 1      |
| FGFR3    | 0     | 1     | 1    | 1     | 2     | 0     | 1      |
| RET      | 1     | 1     | 1    | 1     | 2     | 0     | 1      |
| NTRK2    | 1     | 1     | 1    | 1     | 2     | 0     | 1      |
| EPHA1    | 1     | 1     | 1    | 1     | 2     | 0     | 1      |
| ERBB3    | 1     | 2     | 0    | 1     | 2     | 0     | 0      |
| TIE1     | 1     | 1     | 1    | 1     | 1     | 0     | 1      |
| VEGFR3   | 0     | 1     | 1    | 1     | 1     | 0     | 2      |
| EPHA2    | 1     | 1     | 0    | 2     | 1     | 0     | 1      |
| EPHA4    | 1     | 1     | 1    | 3     | 1     | 0     | 0      |
| EPHA7    | 0     | 0     | 1    | 1     | N     | 0     | 3      |
| PDGFRB   | 0     | 1     | 1    | 1     | 1     | 0     | 1      |
| FLT3     | 0     | 1     | 1    | 1     | 1     | 0     | 1      |
| CSF1R    | 0     | 1     | 1    | 1     | 1     | 0     | 1      |
| EPHB6    | 0     | 0     | 1    | 1     | 1     | 1     | 1      |
| ERBB2    | 1     | 1     | 0    | 1     | N     | 0     | 1      |
| NTRK1    | 0     | 1     | 1    | 1     | N     | 0     | 1      |
| AXL      | 0     | 0     | 0    | 1     | 0     | 0     | 3      |
| VEGFR1   | 0     | 1     | 1    | 1     | 1     | 0     | 1      |
| EPHB1    | 0     | 1     | 0    | 1     | 0     | 1     | 0      |
| EPHB4    | 0     | 0     | 1    | 1     | 1     | 1     | 0      |
| FGFR1    | 0     | 0     | 1    | 1     | 1     | 0     | 0      |
| NTRK3    | 0     | 0     | 0    | 1     | 1     | 0     | 1      |
| MUSK     | 0     | 0     | 0    | 1     | 1     | 0     | 1      |
| FGFR4    | 0     | 0     | 0    | 1     | 1     | 0     | 0      |
| KIT      | 0     | 1     | 0    | 0     | 0     | 0     | 1      |
| EPHA3    | 1     | 0     | 0    | 1     | 0     | 0     | 0      |
| MET      | 0     | 0     | 0    | 0     | N     | 0     | 0      |
| EPHA6    | 0     | 0     | 0    | 0     | N     | 0     | 0      |

The phosphorylation of each RTK spotted onto the phospho array represented by signal density was assessed on a scale of 0–5, 0 being no detectable signal and 5 being a very strong signal. The average score across all cell lines was used to determine the overall ranking of RTK phosphorylation. N indicates that the signal was unable to be assessed for this cell line, due to high local background.

Stratech Scientific, Newmarket, UK) using DMSO as a carrier control (0.1%). Cells were incubated for 72 h before being assayed for viability using the CellTiter Aqueous One Solution Cell Proliferation Assay (Promega) following the manufacturer’s instructions. Absorbance at 490 nm was measured on an ELx800 Absorbance Microplate Reader (BioTek).

Caspase-Glo 3/7 apoptosis assay
Quantitation of caspase 3/7 activity using the Caspase-Glo 3/7 Assay (Promega) was performed according to the manufacturer’s instructions. Parallel cultures were counted using a haemocytometer to account for discrepancies in cell number between samples. The signal was quantified using an MLX luminometer (Dynex Technologies, Worthing, UK).

Results
Phosphorylation RTK screen identifies IGF1R as activated in TGCT
Seven TGCT cell lines, including six nonseminomas and one seminoma, were profiled using antibody arrays to determine the major RTKs activated (supplementary material, Figure S1). The average over all cell lines was used to rank the activity of the RTKs (Table 1). IGF1R was the RTK with the most activity, five out of seven lines showing high levels of phosphorylation. The insulin receptor, which can heterodimerize with IGF1R, also demonstrated high levels of phosphorylation in a similar pattern to IGF1R, consistent with the concept that the IGF pathway is active in TGCT.

© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org
Validation of IGF1R phosphorylation in TGCT cell lines

Two approaches were used to substantiate high IGF1R activity. Phosphorylation of IGF1R in TGCT cell lines was initially confirmed using a phospho-IGF1R ELISA assay including response to IGF1R ligands IGF-1 and IGF-2 (Figure 1A), followed by immunoprecipitation (IP) of IGF1R and immunoblotting with anti-phosphotyrosine antibodies (Figure 1B). The ELISA and immunoprecipitation assays indicated that unstimulated IGF1R phosphorylation levels were generally low, with the only seminoma cell line, TCAM2, having detectable levels by IP. However, four of the six non-seminoma cell lines (GCT44, NTERA2, TERA1, and 577MF) showed a robust response to IGF-1 and IGF-2 stimulation by ELISA and IP. Upon IGF-1 stimulation, TCAM2 showed moderate pIGF1R levels by ELISA but no increase by IP. GCT27 and 2102, which had the lowest pIGF1R levels on the RTK arrays, showed little or no increase in activity when stimulated by IGFs using either method.

IGF1R activity induces AKT signalling

The levels of pAKT induction when the IGF1R pathway is activated were also investigated (Figure 1C). GCT44, NTERA2, and 577MF showed high levels of pAKT in response to IGF-1 stimulation, whereas TERA1 showed a more modest induction. pAKT was undetectable in 2102 cells and did not increase with IGF-1 stimulation in TCAM2 cells. Although GCT27 cells had low amounts of pIGF1R, an increase in pAKT levels was observed with IGF-1 stimulation. Together, these results support IGF pathway activity and response to ligand in four out of six non-seminoma cell lines, which was not seen in the seminoma cell line.

IGF1R is highly expressed in normal testes and clinical TGCT samples

The expression level of IGF1R was analysed in tumour samples by RT-qPCR. Expression of IGF1R was significantly higher in both non-seminomas and seminomas than in normal tissues (p = 0.005 and p = 0.013, respectively; two-tailed t-test with Welch’s correction) (Figure 2A). However, the difference between non-seminomas and seminomas did not reach statistical significance (p = 0.0768). The median expression of IGF1R in normal tissues was considerably lower than in normal testis (0.28-fold, data not shown), indicating that IGF1R expression is relatively high in normal testis. All but one non-seminoma sample demonstrated higher IGF1R expression than the median of the normal tissue panel.

IGF1R expression in TGCT was also investigated by immunohistochemistry on tissue microarrays representing 178 cases. Overall, 73/148 (49%) non-seminomas expressed IGF1R (Figure 2B) and the majority of seminomas and germ cell neoplasia in situ cases were positive (Table 2, Figure 2B, and supplementary material, Table S2). A chi-squared test for trend analysis to detect a difference between staining in non-seminomas and seminomas approached significance (p = 0.0531).

IGF1R knockdown reduces growth and causes apoptosis in non-seminoma cells

The functional consequences of silencing IGF1R expression were assessed in cell lines. NTERA2 and GCT44 were chosen as model non-seminoma cell lines as they both have high activation of IGF1R. siRNA knockdown with two different siRNAs resulted in a strong reduction in viability in both NTERA2 (45% reduction at 96h post-transfection) and GCT44 (60% reduction at 96h post transfection) relative to the non-targeting siRNA (Figure 3A–C and supplementary material, Figure S2A) in comparison to a milder phenotype observed in TCAM2 (25% reduction at 96h post-transfection).

Lentiviral IGF1R shRNAs were used to study the long-term effects of IGF1R knockdown. The growth of both non-seminoma cell lines was severely affected after shRNA-mediated reduction of IGF1R. By day 17 post-transduction, IGF1R-silenced cells of
IGF1R silencing leads to attenuated phospho-AKT signalling in nonseminoma cells and correlates with sensitivity to the IGF1R inhibitor NVP-AEW541. In order to assess the therapeutic potential of targeting IGF1R in TGCT, NVP-AEW541, an IGF1R inhibitor, was used in GI50 assays (Figure 4A). The IGF1R inhibitor was effective at inhibiting IGF1R and AKT phosphorylation in response to IGF-1 stimulation at all concentrations in all cell lines (Figure 4B–D). The most sensitive cell lines were those that had shown high levels of IGF1R phosphorylation in response to IGF stimulus. The seminoma cell line TCAM2 was one of the most resistant lines to NVP-AEW541 inhibition, consistent with a mild phenotypic response to IGF1R silencing, and the 2102 cell line, which demonstrated the lowest phospho-AKT levels, was the most resistant. Sensitivity to NVP-AEW541 in our cell line panel broadly reflects IGF1R activity, although the GCT27 cell line was moderately sensitive despite having very low levels of phospho-IGF1R. The low activity of IGF1R in GCT27 may significantly alter downstream signalling. To investigate this possibility, we assessed the effects of silencing IGF1R on signalling pathways downstream of IGF1R in response to IGF-1 stimulation (Figure 5). In cell lines that appear to depend on IGF1R signalling, such as GCT44, and have the highest sensitivity to an IGF1R inhibitor, such as TERA1, siRNA-mediated downregulation of IGF1R led to decreased phospho-AKT when stimulated with IGF-I (Figure 5A, B). This was also the case for the GCT27 line (Figure 5C), whereas phospho-AKT levels did not alter when IGF1R was silenced in TCAM2 cells, which do not have a high dependence on IGF1R signalling and are more resistant to the inhibitor (Figure 5D). Changes

Table 2. IGF1R staining of TGCT primary tumour TMAs

| TMA        | Histological subtype       | No of tumours scored | No of tumours with IGF1R expression | Percentage of tumours with IGF1R expression (%) |
|------------|---------------------------|----------------------|------------------------------------|-----------------------------------------------|
| TMA 1      | GCNIS                     | 14                   | 11                                 | 79                                            |
|            | Seminoma                  | 16                   | 13                                 | 81                                            |
|            | Nonseminoma               | 82                   | 34                                 | 41                                            |
| TMA 2      | Stage 1 nonseminoma       | 66                   | 39                                 | 59                                            |
| Total      | Nonseminoma               | 148                  | 73                                 | 49                                            |
| Total      | All subtypes              | 178                  | 97                                 | 54                                            |

GCNIS: germ cell neoplasia in situ.
Silencing of IGF1R reduces growth in nonseminoma cell lines. Nonseminoma cell lines GCT44 (A) and NTERA2 (B) exhibited reduced growth upon IGF1R knockdown by two independent siRNAs, whereas the seminoma cell line TCAM2 showed only modest growth retardation (C). Following lentiviral transduction of IGF1R shRNA and selection, the nonseminoma cell lines GCT44 (D) and NTERA2 (E) were eliminated by day 18 of culture in contrast to the seminoma cell line TCAM2 (F) and 2102 (H), which demonstrated a small reduction in cell number after 17 days in culture; GCT27 (G) showed an intermediate response.

in the levels of phospho-ERK and phospho-STAT3 upon IGF1R silencing were not observed.

IGF1R protein expression is increased in the acquired cisplatin-resistant TGCT model cell line and IGF1R silencing leads to cisplatin resensitization

IGF1R has previously been implicated in cisplatin resistance in ovarian cancer [41]. We therefore investigated the SuSa cell line model of cisplatin resistance [35] to determine if IGF1R signalling was enhanced in SuSa cisplatin-resistant (SuSa cisR) cells compared with the parental cisplatin-sensitive cells (SuSa cisS). IGF1R protein was upregulated in the resistant cells that increased phospho-AKT signalling when stimulated with IGF-1, and had the highest expression of IGF1R of all the cell lines in this study (Figure 6A, B). The resistant subline also had increased basal phospho-AKT levels compared with the sensitive line (Figure 6B). IGF1R expression and copy number were increased 1.5-fold in the resistant cells compared with the sensitive line (Figure 6C, D). We transduced SuSa cisR cells with either IGF1R shRNA or control non-silencing (NS) lentivirus and following selection in puromycin and replating, we exposed cells to various doses of cisplatin. The GI50 for cisplatin was reduced in the IGF1R shRNA transduced cells compared with the NS-treated cells (Figure 6E). This difference in sensitivity was seen, although there was no clear difference in cell viability (Figure 6F). However, despite effective knockdown (Figure 6G), residual expression remained quite high and could explain this. Overall, this provides evidence for IGF1R activity contributing to cisplatin resistance in TGCT.

Discussion

Here, we have identified active IGF1R signalling and have demonstrated that this plays a key role in maintaining nonseminoma cell viability and can also contribute
Figure 4. Sensitivity of TGCT cell lines to the IGF1R inhibitor NVP-AEW541. (A) The GI50 of TGCT cell lines to NVP-AEW541 was measured following 72 h exposure of varying concentrations of inhibitor (in normal serum). (B–D) Cells were grown in 1% serum overnight (16 h) and then treated with various concentrations of NVP-AEW541 (indicated in μM) for 3 h, after which cells were stimulated with IGF-1 (50 ng/ml) for 15 min before being lysed and subjected to immunoblotting.

Our finding of phosphorylated IGF1R in nonseminoma cells and high IGF1R expression levels in patient samples fits with previous observations noting high serum levels of IGF-2 and IGFBP2 in nonseminoma patients that reduced after treatment [42]. Similarly, the proportion of cleaved IGFBP3 (which promotes proliferation in breast cancer [43]) is greater in nonseminoma patients and declines upon response to treatment.

The RTK KIT and the chemokine receptor CXCR4 are involved in the survival and migration of TGCTs and also PGCs, the likely precursor cells of TGCT [1,19,36]. IGF1R signalling is also required for the development of PGCs and gonocytes. Zebrafish models have shown that the IGF1Rb isoform is required for proper migration and maintenance of PGC numbers until they reach the genital ridge [2]. Notably, IGF signalling is also required for maintaining the germ cell population in postnatal mice with unilateral undescended testis in both the affected testis and the contralateral descended testis [44]. Blockade of IGF1R signalling or the downstream PI3K pathway resulted in loss of pluripotency in murine neonatal spermatogonial stem cells which is maintained by IGF1 produced by the Leydig cells in vivo [45]. Together with our data, this points to TGCT retaining or recapitulating the IGF1R signalling observed in the germ cell lineage.

Our data demonstrating that activation of IGF1R signalling contributes to nonseminoma cell survival are similar to the functional roles reported for IGF1R in other cancers, including prostate, breast, and colorectal cancers [46–48]. Although IGF1R kinase activity can initiate several major signalling cascades including RAS/RAF/MEK/ERK, PI3K/AKT, and STAT3, we did not observe perturbation of ERK or STAT3 signalling in response to silencing IGF1R in TGCT cell lines. Cell lines demonstrating high phospho-AKT in response to IGF1 stimulation, which subsequently decreased upon IGF1R silencing, were the most sensitive to chemical IGF1R inhibition and silencing. In contrast, the two least sensitive cell lines either had very low phospho-AKT levels (in cell line 2102, levels were undetectable) or did not alter phospho-AKT when IGF1R was downregulated (TCAM2). In addition, the GCT27 cell line, which had little active IGF1R, nonetheless exhibited decreased AKT signalling when IGF1R expression was reduced and was moderately sensitive to the IGF1R inhibitor, as well as demonstrating an intermediate proliferative response to shRNA-mediated silencing. Therefore, AKT signalling appears to be a key response to IGF1R activation in TGCT cells. This is consistent with data for rhabdomyosarcomas, where sensitivity to IGF1R inhibitors was reversed by constitutively active AKT and, conversely, progression of in vivo tumour models was associated with AKT reactivation [49].

To date, few studies have evaluated the roles of RTKs in nonseminomas. A patient with cisplatin-resistant TGCT responded to trastuzumab, suggesting that...
Figure 6. Upregulation of IGF1R protein and pathway activation in SuSa cisplatin-resistant (cisR) cells. (A) IGF1R and phospho-AKT are upregulated in the SuSa cisR subline compared with the parental sensitive cells (cisS) and show a hyperactive response to IGF-1 stimulation. (B) SuSa cisR cells have the highest IGF1R expression across all the cell lines used in the study. IGF1R mRNA expression (C) and copy number (D) are increased in SuSa cisR cells compared with their cisplatin-sensitive counterpart. (E) Reduced IGF1R expression following shRNA lentiviral transduction results in sensitization of SuSa cells to cisplatin. (F) Cell viability in the absence of cisplatin treatment was measured as part of the experiment shown in E and normalized to the control shRNA-treated cells. (G) Immunoblot confirming reduced expression in IGF1R shRNA-treated cells. Densitometry data corresponding to the blots in A and B are shown in the supplementary material, Figure S5.

ERBB2 may be an effective target in TGCT [50]. However, subsequent immunohistochemistry shows that ERBB2 expression is infrequent in TGCT and is not associated with poorer overall survival [51–54]. ERBB3 has been reported as highly expressed in TGCT tumours with signal activation dependent on ERBB2 activation with which it forms heterodimers. Use of lapatinib, a dual ERBB1 and ERBB2 inhibitor, reduced tumour growth in an orthotopic animal model, suggesting that it may be of benefit to a subset of TGCT patients [55]. EGFR is expressed by 21–89% of nonseminoma samples [51,52,56,57] and PDGFRβ has been linked to cisplatin resistance [58]. Recently, ERBB2, EGFR, IGF1R, and other kinases have been investigated in cell lines [59]. Consistent with these studies, our phospho-RTK array screen identified EGFR and PDGFRβ as the fifth and sixth most active RTKs in TGCT cell lines, with ERBB receptors ranking lower. Interestingly, activation of additional RTKs was identified in our screen including TYRO3 and EPHB2. Their role in TGCT remains to be elucidated.

Unlike many solid tumours, TGCT cells readily undergo apoptosis in response to DNA-damaging agents such as cisplatin via a p53-dependent pathway. The p53 transcriptional response to DNA damage appears intact but leads to apoptosis in preference to cell cycle arrest, due in part to very low levels of p21 in TGCT cells [60]. In cases of cisplatin resistance, AKT has been shown to be essential for high cytoplasmic p21 expression, which when reversed by AKT inhibition restores cisplatin sensitivity [61]. AKT1 mutations have recently been identified exclusively in cisplatin-resistant germ cell tumours [62], and copy number gain and concomitant overexpression of AKT1 were a frequent event in a study of intracranial germ cell tumours, which although clinically and histologically similar to gonadal germ cell tumours, are more likely to be refractory to treatment [63]. Phospho-AKT levels are significantly higher in cisplatin-resistant TGCT cells compared with sensitive or untreated tumours [58]. This is consistent with our finding that in one TGCT model of acquired cisplatin resistance, IGF1R copy number and mRNA expression were increased in the cells with cisplatin resistance, accompanied by elevated IGF1R and phospho-AKT protein levels. Importantly, reducing IGF1R expression in the resistant subline resensitized cells to cisplatin, showing that upregulation of IGF1R can contribute to cisplatin resistance in TGCT.

Single-agent clinical trials employing IGF1R inhibitors have been largely disappointing, due to a lack of both wide-scale efficacy and accurate predictive biomarkers of response. There is conflicting evidence as to whether expression of IGF1R itself, as opposed to activated IGF1R, identifies patients as suitable for IGF1R-targeted therapy [49,64–66]. Our data identify AKT pathway activation in response to IGF1R signalling as a key factor. IGF1R inhibition has resulted in enhanced sensitivity to general cytotoxic and radiation-based therapies in other cancers [67–69], and recent results for TGCT cell lines show positive but mixed results for cisplatin combined with mTOR, EGFR, and IGF1R inhibitors [59]. Together with our results, this raises the possibility that combination of IGF1R inhibition with chemotherapy could promote resensitization to treatment in chemo-resistant disease.

Acknowledgements

We thank Ryan Bishop for technical assistance with lentivirus testing and Gabrielle Elshtein from University College London Advanced Diagnostics for undertaking IGF1R IHC staining. We acknowledge NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research (ICR). We also acknowledge support from The Bob Champion Fund.
Cancer Trust (DG) and the Medical Research Council (grant G0801477).

Author contributions statement
JS, NCG, AM, and JMS designed the study. JS, NCG, KRT, and JR carried out and interpreted experiments. JS, NCG, SDP, and KT analysed data. JS, NCG, BMS, RAH, and JMS were involved in data interpretation. JS, NCG, DCG, and JMS wrote the manuscript with contributions and approval from all authors.

References
1. Gilbert D, Rapley E, Shipley J. Testicular germ cell tumours: predisposing genes and the male germ cell niche. Nat Rev Cancer 2011; 11: 278–288.
2. Schlueuter PJ, Sang X, Duan C, et al. Insulin-like growth factor receptor Ibeta is required for zebrafish primordial germ cell migration and survival. Dev Biol 2007; 305: 377–387.
3. Dolci S, Williams DE, Ernst MK, et al. Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature 1991; 352: 809–811.
4. Farini D, La Sala G, Tedesco M, et al. Chemoattractant action and molecular signaling pathways of Kit ligand on mouse primordial germ cells. Dev Biol 2007; 306: 572–583.
5. Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer. Ann Oncol 2013; 24: 878–888.
6. Anon. http://seer.cancer.gov/archive/csr/1975_2004/results figure/ sect_01_zfig.19.pdf.
7. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8: 3034–3038.
8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24.
9. Sridhar SS, Seymor L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003; 4: 397–406.
10. McIntyre A, Summersgill B, Jafer O, et al. Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene 2004; 23: 9142–9147.
11. McIntyre A, Summersgill B, Grygalewicz B, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005; 65: 8085–8089.
12. Izquierdo MA, Van der Valk P, Van Ark-Otte J, et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol 1995; 177: 253–258.
13. Leroy X, Augusto D, Leteurtre E, et al. CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histoch Cytoch 2002; 50: 283–285.
14. Nikolau M, Valavanis C, Aravantinos G, et al. Kit expression in male germ cell tumors. Anticancer Res 2007; 27: 1685–1688.
15. Went PT, Dimhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004; 22: 4514–4522.
16. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164: 305–313.
17. Loosjenga LHJ, de Leeuw H, van Oorschot M, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003; 63: 7674–7678.
18. Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 2008; 47: 34–42.
19. Goddard NC, McIntyre A, Summersgill B, et al. KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature. Int J Androl 2007; 30: 337–348; discussion 349.
20. Di Vizio D, Cito L, Boccia A, et al. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 2005; 24: 1882–1894.
21. McIntyre A, Gilbert D, Goddard N, et al. Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. Genes Chromosomes Cancer 2008; 47: 547–557.
22. Gilbert DC, McIntyre A, Summersgill B, et al. Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes Chromosomes Cancer 2011; 50: 186–195.
23. Zafarana G, Grygalewicz B, Gillis AJM, et al. 12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH. Oncogene 2003; 22: 7695–7701.
24. McIntyre A, Summersgill B, Spedlove HE, et al. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia 2005; 7: 1047–1052.
25. Sommerer F, Hengge UR, Markwardh A, et al. Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer 2005; 115: 329–335.
26. Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009; 27: 2129–2136.
27. Litchfield K, Levy M, Huddart RA, et al. The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. Nat Rev Urol 2016; 13: 409–419.
28. Andrews PW, Bronson DL, Benham F, et al. A comparative study of eight cell lines derived from human testicular teratocarcinoma. Int J Cancer 1980; 26: 269–280.
29. Andrews PW, Goodfellow PN, Shervinsky LH, et al. Cell-surface antigens of a clonal human embryonal carcinoma cell line: morphological and antigenic differentiation in culture. Int J Cancer 1982; 29: 523–531.
30. Andrews PW, Damjanov I, Simon D, et al. Phosphopotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab Invest 1984; 50: 147–162.
31. Pera MF, Blasco Lafita MJ, Milis J. Cultured stem-cells from human testicular teratomas: the nature of human embryonal carcinoma, and its comparison with two types of yolk-sac carcinoma. Int J Cancer 1987; 40: 334–343.
32. Summersgill B, Osin P, et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. Diagn Mol Pathol 1998; 7: 260–266.
33. Mizuno Y, Gotoh A, Kamidono S, et al. Establishment and characterization of a new human testicular germ cell tumor cell line (TCam-2). Nihon Hinyokika Gakkai Zasshi 1993; 84: 1211–1218 (in Japanese).
38. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods* 2012; 9: 676–682.

39. Schindelin J, Rueden CT, Hiner MC, et al. The ImageJ ecosystem: an open platform for biomedical image analysis. *Rep Produc Dev* 2015; 82: 518–529.

40. Tonelli R, McIntyre A, Camerin C, et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigen therapy. *Clin Cancer Res* 2012; 18: 796–807.

41. Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. *Cancer Res* 2009; 69: 2996–3003.

42. Fottner C, Sattarova S, Hoffmann K, et al. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin. *Eur J Endocrinol* 2008; 159: 317–327.

43. Mitsu Y, Mochizuki S, Kodama T, et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. *Cancer Res* 2006; 66: 9013–9020.

44. Bingol-Kololgu M, Bahadir GB, Vargun R, et al. Effects of local and sustained release of FGF, IGF, and GH on germ cells in unilateral descended testis in rats. *Urology* 2010; 75: 223–228.

45. Huang Y-H, Chin C-C, Ho H-N, et al. Pluripotency of mouse spermatogonial stem cells maintained by IGF-I-dependent pathway. *FASEB J* 2009; 23: 2076–2087.

46. Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. *Cancer Res* 2004; 64: 8620–8629.

47. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. *Cancer Res* 2003; 63: 8912–8921.

48. Sekharan M, Zhao H, Sun M, et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-xl pathway. *Cancer Res* 2003; 63: 7708–7716.

49. Cao L, Yu Y, Darko L, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. *Cancer Res* 2008; 68: 8039–8048.

50. Kollmannsberger C, Pressler H, Mayer F, et al. Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. *Ann Oncol* 1999; 10: 1393–1394.

51. Moroni M, Veronese S, Schiavo R, et al. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. *Clin Cancer Res* 2001; 7: 2770–2775.

52. Kollmannsberger C, Mayer F, Pressler H, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. *Cancer* 2002; 95: 301–308.

53. Mándoly L, Géczi L, Bodrogi I, et al. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. *Anticancer Res* 2004; 24: 2219–2224.

54. Mándoly L, Géczi L, Bodrogi I, et al. Expression of HER-2/neu in testicular tumors. *Anticancer Res* 2003; 23: 3447–3451.

55. Julius M, Castillo-Avila W, Vidal A, et al. ErbB3 inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. *Int J Cancer* 2013; 133: 235–246.

56. Hechelhammer L, Störelk S, Odermatt B, et al. Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. *Vircows Arch* 2003; 443: 28–31.

57. Wang X, Zhang S, Maclennan GT, et al. The Journal of Pathology on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com © 2017 The Authors. *Clin Cancer Res* 2016; 22: 92–102.
25 Years ago in the Journal of Pathology...

Immunohistochemical detection of cd1a antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010

Dr. László Krenács, László Tiszalícz, Tibor Krenács and Laurence Boumsell

Genetic alterations of the TP53 gene, p53 protein expression and hpv infection in primary cervical carcinomas

Åslaug Helland, Ruth Holm, Gunnar Kristensen, Janne Kaern, Frank Karlsen, Claes Trope, Jahn M. Nesland and Anne-Lise Børresen

Immunohistochemical evidence for the expression of proliferating cell nuclear antigen (PCNA) by non-proliferating hepatocytes adjacent to metastatic tumours and in inflammatory conditions

Dr. Rebecca F. Harrison, Gary M. Reynolds and David C. Rowlands

To view these articles, and more, please visit: www.thejournalofpathology.com

Click ‘ALL ISSUES (1892 - 2018)’, to read articles going right back to Volume 1, Issue 1.